Apellis Pharmaceuticals Inc
$ 22.13
-1.51%
24 Feb - close price
- Market Cap 2,800,003,000 USD
- Current Price $ 22.13
- High / Low $ 22.67 / 20.10
- Stock P/E 61.47
- Book Value 3.17
- EPS 0.36
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.14 %
- 52 Week High 30.48
- 52 Week Low 16.10
About
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$33.95
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-31 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-01 | 2024-05-07 | 2024-02-27 | 2023-11-01 | 2023-07-31 | 2023-05-04 | 2023-02-21 |
| Reported EPS | 1.67 | -0.33 | -0.74 | -0.29 | -0.4624 | -0.28 | -0.42 | -0.73 | -1.17 | -1.02 | -1.56 | -1.5 |
| Estimated EPS | 1.55 | -0.48 | -0.54 | -0.4019 | -0.3 | -0.32 | -0.47 | -0.69 | -0.86 | -1.32 | -1.46 | -1.57 |
| Surprise | 0.12 | 0.15 | -0.2 | 0.1119 | -0.1624 | 0.04 | 0.05 | -0.04 | -0.31 | 0.3 | -0.1 | 0.07 |
| Surprise Percentage | 7.7419% | 31.25% | -37.037% | 27.8427% | -54.1333% | 12.5% | 10.6383% | -5.7971% | -36.0465% | 22.7273% | -6.8493% | 4.4586% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.379 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APLS
2026-02-25 00:52:25
Apellis Pharmaceuticals (APLS) reported Q4 FY 2025 revenue of US$199.9 million but a basic EPS loss of US$0.47, contrasting with a trailing twelve-month profit of US$0.18 EPS. This shift highlights a debate between sustained revenue growth and inconsistent profitability, with bullish narratives focusing on long-term earnings leverage from SYFOVRE and EMPAVELI, while bearish arguments point to high valuation (125x P/E) and reliance on these key drugs. The current share price of $22.13 is significantly below the DCF fair value of $109.17 and analyst target of $33.58, presenting a valuation gap that bulls see as an opportunity, despite ongoing risks.
2026-02-24 17:52:25
Wedbush has lowered its price target for Apellis Pharmaceuticals (APLS) to $18 from $20 while maintaining a Neutral rating on the stock. This adjustment follows the release of Apellis Pharmaceuticals' Q4 2025 earnings report, which included an EPS of $0.47 and total revenue of $199.9M, exceeding analyst estimates for both figures. The company specializes in treatments for diseases through the inhibition of the complement system, with key products like SYFOVRE and EMPAVELI.
2026-02-24 16:52:25
Apellis Pharmaceuticals, Inc. (APLS) reported strong Q4 results, with earnings of $0.47 per share significantly beating analyst estimates of a loss of $0.4 per share, and revenues of $199.91 million surpassing consensus by 2.85%. Despite these positive results, the stock has seen a decline of 10.6% year-to-date, prompting questions about its future performance. The company currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market in the near future.
2026-02-24 15:52:25
Apellis Pharmaceuticals reported Q4 2025 revenues of $200 million, exceeding forecasts, but an EPS of -$0.379 met expectations, leading to a pre-market stock decline. The company highlighted strong demand for its Syfovre and Empaveli products and anticipates continued revenue growth with modestly higher operating expenses in 2026 due to new trials and milestone payments. Apellis also discussed managing its convertible debt, advancing pipeline innovations like a Syfovre prefilled syringe, and an AI-enabled OCT technology set to drive future growth.
2026-02-24 10:52:25
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) shows a promising investment opportunity by combining strong fundamental growth with a bullish chart setup. The company demonstrates significant sales expansion and a shift towards profitability, with positive future projections. Despite a low technical rating currently, its setup rating suggests a potential breakout from a recent resting range, indicating opportune timing for market re-evaluation.
2026-02-23 14:46:29
Apellis Pharmaceuticals Inc. is set to report fourth-quarter earnings, with investors keenly watching for the potential of its new rare kidney disease therapy, Empaveli, to offset challenges faced by its flagship geographic atrophy drug, Syfovre. Analysts anticipate a loss of 38 cents per share, a reversal from the previous quarter, and are looking for 2026 guidance from management. While Syfovre has seen flat revenue, Empaveli's early launch trajectory in rare kidney diseases has been strong, with analysts projecting significant peak sales.
